Next Article in Journal
Transcellular Transport of Heparin-coated Magnetic Iron Oxide Nanoparticles (Hep-MION) Under the Influence of an Applied Magnetic Field
Next Article in Special Issue
Quantitative Determination of ABT-925 in Human Plasma by On-Line SPE and LC-MS/MS: Validation and Sample Analysis in Phase II Studies
Previous Article in Journal
Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies
Previous Article in Special Issue
Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent γ-Ketoaldehyde Scavenger, by LC/MS/MS
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2010, 2(2), 105-118;

Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma

Charles River Laboratories, 334 South Street, Shrewsbury, MA 01545, USA
Covance Laboratories, 3301 Kinsman Boulevard, Madison, WI 53704, USA
Sepracor Inc., 84 Waterford Drive, Marlborough, MA 01752, USA
Author to whom correspondence should be addressed.
Received: 20 January 2010 / Revised: 26 March 2010 / Accepted: 31 March 2010 / Published: 1 April 2010
(This article belongs to the Special Issue Applications of Hyphenated Chromatography Techniques in Pharmaceutics)
Full-Text   |   PDF [384 KB, uploaded 1 April 2010]   |  


A novel bioanalytical method was developed and validated for the quantitative determination of erlotinib in human plasma by using the supported liquid extraction (SLE) sample cleanup coupled with hydrophilic interaction liquid chromatography and tandem mass spectrometric detection (HILIC-MS/MS). The SLE extract could be directly injected into the HILIC-MS/MS system for analysis without the solvent evaporation and reconstitution steps. Therefore, the method is simple and rapid. In the present method, erlotinib-d6 was used as the internal standard. The SLE extraction recovery was 101.3%. The validated linear curve range was 2 to 2,000 ng/mL based on a sample volume of 0.100-mL, with a linear correlation coefficient of > 0.999. The validation results demonstrated that the present method gave a satisfactory precision and accuracy: intra-day CV < 5.9% (<8.4% for the lower limit of quantitation, LLOQ) with n = 6 and the accuracy of 98.0–106.0%; inter-day CV < 3.2% (<1.5% for LLOQ) with n = 18 and the accuracy of 100.0–103.2%. A dilution factor of 10 with blank plasma was validated for partial volume analysis. The stability tests indicated that the erlotinib in human plasma is stable for three freeze-thaw cycles (100.0–104.5% of the nominal values), or 24-h ambient storage (100.0–104.8% of the nominal values), or 227-day frozen storage at both -20 ºC (91.5–94.5% of the nominal values) and -70 ºC (93.3–93.8% of the nominal values). The results also showed no significant matrix effect (<6.3%) even with direct injection of organic extract into the LC-MS/MS system. The validated method has been successfully applied to support a clinical study. View Full-Text
Keywords: supported liquid extraction (SLE); erlotinib; HILIC-MS/MS; human plasma supported liquid extraction (SLE); erlotinib; HILIC-MS/MS; human plasma

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Pan, J.; Jiang, X.; Chen, Y.-L. Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma. Pharmaceutics 2010, 2, 105-118.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top